2025
KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection
Fagerberg E, Attanasio J, Dien C, Singh J, Kessler E, Abdullah L, Shen J, Hunt B, Connolly K, De Brouwer E, He J, Iyer N, Buck J, Borr E, Damo M, Foster G, Giles J, Huang Y, Tsang J, Krishnaswamy S, Cui W, Joshi N. KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection. Science 2025, 387: eadn2337. PMID: 39946463, PMCID: PMC12199163, DOI: 10.1126/science.adn2337.Peer-Reviewed Original ResearchConceptsCD8 T cellsT cellsCD8 T cell exhaustionNaive CD8 T cellsAcute LCMV infectionT cell exhaustionT cell fate decisionsLineage fidelityLCMV infectionEffector differentiationAcute infectionExhaustion programTranscription factorsImmune responseEpigenetic modulationSuppress differentiationProgenitor stateKLF2InfectionFunctional stateFate decisionsCD8
2023
Single-cell epigenetic, transcriptional, and protein profiling of latent and active HIV-1 reservoir revealed that IKZF3 promotes HIV-1 persistence
Wei Y, Davenport T, Collora J, Ma H, Pinto-Santini D, Lama J, Alfaro R, Duerr A, Ho Y. Single-cell epigenetic, transcriptional, and protein profiling of latent and active HIV-1 reservoir revealed that IKZF3 promotes HIV-1 persistence. Immunity 2023, 56: 2584-2601.e7. PMID: 37922905, PMCID: PMC10843106, DOI: 10.1016/j.immuni.2023.10.002.Peer-Reviewed Original ResearchConceptsTranscription factor accessibilityHIV-1-infected cellsFactor accessibilityHIV-1 persistenceHeterogeneous cellular statesEpigenetic programsCellular programsCellular statesLatent HIV-1-infected cellsProliferation programProtein profilingSuppressive antiretroviral therapyHIV-1 eradicationHIV-1 reservoirCell deathProtein statesHIV-1 RNAAP-1HIV-1 DNASurface proteinsMechanistic interrogationEpigeneticsAntiretroviral therapyMemory CD4Effector differentiationStem-like CD4 T differentiation controls CD8 T cell immunity or tolerance in cancer
Cardenas M, Prokhnevska N, Jansen C, Sobierajska E, Master V, Kissick H. Stem-like CD4 T differentiation controls CD8 T cell immunity or tolerance in cancer. The Journal Of Immunology 2023, 210: 86.04-86.04. DOI: 10.4049/jimmunol.210.supp.86.04.Peer-Reviewed Original ResearchTumor-draining lymph nodesAnti-tumor responsesCD4 T cellsEffector differentiationT cellsT-cell anti-tumor responseTumor-specific CD4 T cellsCD8 T cell responsesCD8 T cell immunityT cell effector differentiationCD4 T cell differentiationReduced tumor burdenT cell responsesT cell immunityDraining Lymph NodesT cell differentiationStem-like propertiesExpression of TCF1Tumor responseTumor burdenTreg differentiationLymph nodesCancer responseCD4 differentiationCD8GOT1 regulates CD8+ effector and memory T cell generation
Xu W, Patel C, Zhao L, Sun I, Oh M, Sun I, Helms R, Wen J, Powell J. GOT1 regulates CD8+ effector and memory T cell generation. Cell Reports 2023, 42: 111987. PMID: 36640309, PMCID: PMC9943022, DOI: 10.1016/j.celrep.2022.111987.Peer-Reviewed Original ResearchConceptsIntracellular redox balancePosttranslational regulationHIF proteinsMetabolic reprogrammingRedox balanceΑ-ketoglutarateGOT1T cell activationCell generationGenetic deletionEffector differentiationCritical roleCell activationDifferentiationRegulationProliferationReprogrammingBiosynthesisEffectorsProteinDeletionMechanisticallyCytotoxic functionFunctionPurine
2022
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
Prokhnevska N, Cardenas M, Valanparambil R, Sobierajska E, Barwick B, Jansen C, Reyes Moon A, Gregorova P, delBalzo L, Greenwald R, Bilen M, Alemozaffar M, Joshi S, Cimmino C, Larsen C, Master V, Sanda M, Kissick H. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 2022, 56: 107-124.e5. PMID: 36580918, PMCID: PMC10266440, DOI: 10.1016/j.immuni.2022.12.002.Peer-Reviewed Original ResearchConceptsTumor-draining lymph nodesCD8<sup>+</sup> T cell activationT cell activationCD8<sup>+</sup> T cellsStem-like cellsT cellsCell activationEffector differentiationLymph nodesTumor-specific CD8<sup>+</sup> T cellsActivated CD8<sup>+</sup> T cellsAnti-tumor T cell responsesTumor-draining lymph node cellsCD8+ T cell activationCo-StimulationT cell responsesAntigen-presenting cellsMurine tumor modelsResponse to cancerEffector phenotypeTumor immunotherapyTumor modelTumorCell responsesAcute viruses
2006
IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells
Nomura LE, Emu B, Hoh R, Haaland P, Deeks SG, Martin JN, McCune JM, Nixon DF, Maecker HT. IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells. AIDS Research And Therapy 2006, 3: 18. PMID: 16859558, PMCID: PMC1562434, DOI: 10.1186/1742-6405-3-18.Peer-Reviewed Original ResearchHIV-specific CD8HIV-positive subjectsHIV-specific T cellsCMV-specific T cellsEffector cell differentiationT cellsIL-2Effector cellsIL-2 production correlatesMemory/effector phenotypeTerminal effector cellsAntigen-specific CD8Cytokine flow cytometryHIV-negative subjectsIL-2 productionCD27-CD28HIV-negativeCytokine profileProgressive diseaseEffector phenotypeHIV-specificEffector differentiationCD8Cell differentiationCell frequency
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply